The place of bevacizumab in the management of advanced non-small cell lung cancer (NSCLC) was reviewed. Particular reference has been made to the recent research on the systemic treatment of NSCLC indicating that treatment tailored to specifically identified morphology or genetic profile has recently changed practice. The result of this recent research means that bevacizumab has little, if any, place in the treatment of NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clon.2014.05.004 | DOI Listing |
Publication Analysis
Top Keywords
non-small cell
8
cell lung
8
lung cancer
8
treatment nsclc
8
bevacizumab non-small
4
cancer overview
4
overview practice
4
practice era
4
era molecular
4
molecular testing
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!